MX2020013689A - Hidroxipropil-?-ciclodextrina novedosa y proceso para la producción de esta. - Google Patents

Hidroxipropil-?-ciclodextrina novedosa y proceso para la producción de esta.

Info

Publication number
MX2020013689A
MX2020013689A MX2020013689A MX2020013689A MX2020013689A MX 2020013689 A MX2020013689 A MX 2020013689A MX 2020013689 A MX2020013689 A MX 2020013689A MX 2020013689 A MX2020013689 A MX 2020013689A MX 2020013689 A MX2020013689 A MX 2020013689A
Authority
MX
Mexico
Prior art keywords
cyclodextrin
hpβcd
production
novel
hydroxypropyl
Prior art date
Application number
MX2020013689A
Other languages
English (en)
Spanish (es)
Inventor
Clothilde Buffe
Vincent Wiatz
Joël Delattre
Original Assignee
Roquette Freres
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1855952A external-priority patent/FR3083234B1/fr
Application filed by Roquette Freres filed Critical Roquette Freres
Publication of MX2020013689A publication Critical patent/MX2020013689A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
MX2020013689A 2018-06-29 2019-06-28 Hidroxipropil-?-ciclodextrina novedosa y proceso para la producción de esta. MX2020013689A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1855952A FR3083234B1 (fr) 2018-06-29 2018-06-29 Nouvelles hydroxypropyl-beta-cyclodextrines et leurs procedes de preparation
FR1902375 2019-03-08
PCT/FR2019/051602 WO2020002851A1 (fr) 2018-06-29 2019-06-28 NOUVELLE HYDROXYPROPYL-β-CYCLODEXTRINE ET SON PROCÉDÉ DE PRÉPARATION

Publications (1)

Publication Number Publication Date
MX2020013689A true MX2020013689A (es) 2021-05-12

Family

ID=67551566

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013689A MX2020013689A (es) 2018-06-29 2019-06-28 Hidroxipropil-?-ciclodextrina novedosa y proceso para la producción de esta.

Country Status (10)

Country Link
US (1) US12522670B2 (https=)
EP (1) EP3814386A1 (https=)
JP (2) JP7581055B2 (https=)
KR (1) KR102912248B1 (https=)
CN (1) CN112334494A (https=)
CA (1) CA3104568A1 (https=)
IL (1) IL279845A (https=)
MX (1) MX2020013689A (https=)
SG (1) SG11202013126QA (https=)
WO (1) WO2020002851A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7607935B2 (ja) 2019-01-03 2025-01-06 サイクラリティ・セラピューティクス・インコーポレイテッド シクロデキストリン二量体、それらの組成物、及びそれらの使用
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
JP2024064599A (ja) * 2022-10-28 2024-05-14 国立大学法人 熊本大学 細胞内コレステロール輸送障害に起因する疾患又は障害の治療、予防又は改善用組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
HK1009335A1 (en) * 1989-04-03 1999-05-28 Janssen Pharmaceutica N.V. Regioselective substitutions in cyclodextrins
US5096893A (en) 1989-04-03 1992-03-17 The United States Of America As Represented By The Department Of Health And Human Services Regioselective substitutions in cyclodextrins
KR920008700A (ko) * 1990-10-29 1992-05-28 이헌조 데크의 테이프 삽입유무 표시방법
DE19505263A1 (de) * 1995-02-16 1996-08-22 Consortium Elektrochem Ind Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
CN1155888A (zh) * 1995-06-08 1997-07-30 火箭兄弟公司 粉状羟丙基-β-环糊精组合物和其制备方法
FR2735136B1 (fr) * 1995-06-08 1997-08-14 Roquette Freres Composition pulverulente d'hydroxypropyl-betacyclodextrine et son procede de preparation.
FR2738149B1 (fr) * 1995-09-06 1997-11-14 Chauvin Lab Sa Collyre a base d'indometacine pret a l'emploi
US5744154A (en) 1995-09-06 1998-04-28 Laboratoire Chauvin S.A. Ready-to-use indomethacin-based eye lotion
EP1655034A1 (en) 2004-10-10 2006-05-10 Université de Liège Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases.
WO2012037117A1 (en) 2010-09-13 2012-03-22 Bev-Rx, Inc. Aqueous drug delivery system comprising off - flavor masking agent
CN102558394B (zh) * 2010-12-07 2014-11-12 石药集团中奇制药技术（石家庄）有限公司 羟丙基-β-环糊精的制备方法
CN102040675B (zh) * 2010-12-22 2012-10-03 石药集团中诺药业（石家庄）有限公司 一种羟丙基-β-环糊精的制备方法
US8791269B2 (en) 2011-07-01 2014-07-29 Fondazione Istituto Insubrico Di Ricerca Per La Vita Complex of amorphous tomoxiprole and cyclodextrin with fast dissolution rate and process for the preparation thereof
FR3014694B1 (fr) * 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
CA2988529A1 (en) 2015-06-10 2016-12-15 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
CN108034010A (zh) * 2017-12-29 2018-05-15 山东滨州智源生物科技有限公司 一种羟丙基环糊精的绿色制备方法

Also Published As

Publication number Publication date
US12522670B2 (en) 2026-01-13
EP3814386A1 (fr) 2021-05-05
JP2024150779A (ja) 2024-10-23
KR20210027279A (ko) 2021-03-10
IL279845A (en) 2021-03-01
JP2021529243A (ja) 2021-10-28
SG11202013126QA (en) 2021-02-25
JP7581055B2 (ja) 2024-11-12
KR102912248B1 (ko) 2026-01-15
US20210253746A1 (en) 2021-08-19
WO2020002851A1 (fr) 2020-01-02
CA3104568A1 (fr) 2020-01-02
CN112334494A (zh) 2021-02-05

Similar Documents

Publication Publication Date Title
DOP2017000117A (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
PY21109835A (es) Compuestos novedosos, métodos para su fabricación, y usos de los mismos
UY39011A (es) Métodos para purificar cannabinoides, composiciones y kits de estos
CR20160352A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CO6670589A2 (es) Compuestos para reducir la producción de beta-amiloide
DOP2017000118A (es) 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1
CO7230336A2 (es) Inhibidores de indazol de la ruta de señalización de wnt y usos terapeúticos de los mismos
DOP2017000013A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
MX2020013689A (es) Hidroxipropil-?-ciclodextrina novedosa y proceso para la producción de esta.
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
UY37378A (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus
CL2019002079A1 (es) Sales del inhibidor de pim quinasa; útiles en el tratamiento del cáncer. (divisional solicitud 201800611)
MX2016010476A (es) Novedoso proceso para preparar silices precipitadas, novedosas silices precipitadas, y sus usos, en particular para reforzar polimeros.
CL2012002570A1 (es) Compuestos derivados de ácido 2-(3heteroaril-amino-1,2,3,4-tetrahidro-9h-carbazol)-acético, composicion farnaceutica que los comprende, y su uso como medicamentos, en la profilaxis y/o el tratamiento de patologias mediadas por la modulacion de receptores de prostaglandinas d2, como trastornos alergicos o inmunitarios.
DOP2017000123A (es) Análogos de urea unidos sustituidos como moduladores de sirtuina
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
BR112014027965A2 (pt) composições de polimorfos, métodos de produção, e usos das mesmas
MX2019007101A (es) Derivados de oxazina como inhibidores de beta secretasa y metodos de uso.
MX2019007102A (es) Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
MX2019000982A (es) Compuestos y composiciones y usos de los mismos.
GT200600274A (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador saturado y su uso como agentes farmacétuicos
GT200900150A (es) Nuevos compuestos azabiciclicos, un proceso para su preparacion y las composiciones farmaceuticas que los contienen.
CU20190077A7 (es) Eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso
BR112014026453A2 (pt) composição farmacêutica de liberação retardada, processo para o preparo de uma composição farmacêutica compreendendo salsalato e método de tratar sinais e sintomas de artrite reumatóide, osteoartrite e desordens reumáticas relacionadas
PY1515875A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO (3,4-d)(1,3)TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS.